Articles tagged with Blood Cancer
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
Researchers at the University of Pennsylvania have discovered a new approach to triggering differentiation in AML cells, potentially treating a wider range of patients. By inhibiting an enzyme that blocks cellular differentiation, AML cells can lose aggressive growth traits and mature into new cell types.
A new treatment target for lymphoma has been identified as protein KDM5, which may reverse the effects of KMT2D mutations in cancer cells. The international collaboration aims to identify patient groups most likely to benefit from this type of treatment and explore its therapeutic potential across various lymphoma subtypes.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers developed a novel model to identify specific genes and genetic alterations in multiple myeloma, stratifying the cancer's severity via DNA and RNA sequencing. This model revealed diverse subtypes and high-risk patients beyond current classifications.
A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...
Researchers have developed a new method of stem cell transplantation that does not require chemotherapy or radiation. The approach uses immunotherapeutic drugs to eliminate cancer cells and prevent immune rejection. This technique has the potential to be curative for blood cancers and treat other diseases like sickle cell anemia.
People with blood cancers are at higher risk of severe COVID-19 illness; research suggests they don't always achieve optimal protection from vaccination. A new study found that patients with lymphoma were more likely to develop post-vaccination COVID-19 infection compared to those with other blood cancers.
A study suggests that suppressing the protective mechanisms of rogue blood stem cells can help curb clonal hematopoiesis and prevent leukemia. The researchers used zebrafish with colored 'barcodes' to track the dominance of cancerous clones, revealing a connection between anti-inflammatory genes and resistance to inflammation.
Ulrich Steidl, a leading cancer researcher, has received an NCI grant to study the molecular mechanisms of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The goal is to develop new treatments and cures for these fatal disorders.
A study found that over half of double-vaccinated blood cancer patients have poor immune responses to COVID-19. Despite being vaccinated, these patients remain vulnerable to severe infection and are urged to continue wearing masks and maintaining social distancing.
Researchers found that adding interferon to bone marrow transplant significantly reduced leukemia relapse among high-risk patients, improving outcomes. The study suggests a potential new strategy for treating advanced acute myeloid leukemia, with further research needed to confirm the findings.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
Researchers at CNIO and 12 de Octubre Hospital have developed a new cancer treatment called CAR-NK-cell immunotherapy, which uses natural killer cells to target cancerous cells. The treatment has shown promising results in mice with multiple myeloma, with 25% of treated mice remaining disease-free.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A genetic analysis reveals that a rare type of blood cancer affecting immune T cells may be caused by exposure to smoking and aging-related mutations in blood precursor cells. The study found a potential link between the development of these tumours and second-hand smoke, suggesting cessation may prevent their occurrence.
Researchers at the University of Basel have discovered a novel combination therapy approach that combines inhibiting JAK2 with targeting the MAPK signaling pathway. This dual targeting strategy has shown promising results in improving leukemia treatment outcomes by reducing blood cell production and altering disease course.
Researchers from Pusan National University have compiled a comprehensive review of ginsenosides, the main component of ginseng, which can prevent inflammation, diabetes, and cancer. The study provides insights into how to improve ginsenoside production through chemical and enzymatic treatments, as well as microbial action.
Researchers identified DNA mutations from platinum-based chemotherapies in AML patients, suggesting treatment-associated cancer development. The study's findings imply that clonal hematopoiesis precedes chemotherapy exposure.
Eosinophils, a type of white blood cell, play a crucial role in destroying malignant tumors by recruiting T-cells and releasing destructive proteins. The study, published in Cancer Research, reveals that eosinophils combat cancer effectively but require the help of T-cells to do so.
A new DNA-based test using whole genome sequencing can identify tumour-specific markers to measure cancer levels in children's bodies. This technology has the potential to detect minimal residual disease and change treatment outcomes.
A phase II trial found that high-dose cytarabine followed by pembrolizumab improved cancer remission rates in AML patients, with a complete remission rate of 38%. The treatment also showed promise for patients who had not benefited from standard therapy.
Children genetically predisposed to overproduce lymphocytes in relation to other white blood cells are at higher risk of developing ALL, according to a new USC study. The research found that the ratio of lymphocytes to other key blood cells is significant in predicting leukemia risk.
Researchers found that remnant cholesterol levels above 24 micrograms per deciliter were associated with a 40-50% higher risk of major heart disease or stroke. The study suggests using remnant cholesterol as an additional metric for predicting cardiovascular disease and stroke risk, in addition to LDL cholesterol levels.
A new study from Penn Medicine demonstrates that RN7SL1, a naturally occurring RNA, can activate the body's own natural T cells to seek out cancer cells that have escaped recognition by CAR T cells. This approach may help improve efforts to treat solid tumors.
Researchers discovered that cancer-associated mutations in blood progenitor cells lead to distinct changes in both cancer and non-cancer immune cells in Waldenstrom macroglobulinemia. This finding has potential implications for origins and therapy of the disease, suggesting a new approach to immune therapies.
Silent mutations, which don't change protein sequences, hold diagnostic value in predicting cancer types and patient survival. The study analyzed over 10,000 cancer genomes and found that combining information from silent and non-silent mutations improved classification and prognostication up to 17% and 5%, respectively.
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.
A novel AI-powered blood test, DELFI, has been developed to detect lung cancer with high accuracy. The test uses machine learning to analyze cell-free DNA in the bloodstream and has been shown to identify over 90% of patients with lung cancer.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
Scientists at University of California San Diego School of Medicine have developed a method to keep cultured hematopoietic stem cells healthy, positive news for patients seeking stem cell transplants. The findings also hint at a new way to ward off aging by super-activating the heat shock pathway.
Researchers at UVA Health System discovered that combining drug palbociclib with ruxolitinib could effectively treat myelofibrosis by preventing bone marrow scarring and improving blood cell counts. This potential new treatment offers a promising approach to devastating blood disorder.
A new study published in Blood Cancer Discovery reveals that children with acute myeloid leukemia (AML) who have more DNA changes in their blood stem cells are more likely to survive. The researchers hope that this finding can be used as a tool to identify high-risk patients and improve treatment outcomes.
A world-first study found that cancer patients receiving chemotherapy intravenously have more than double the risk of developing a blood clot or thrombosis if the vein is too small and the catheter occupies more than 45% of the vein. Researchers identified specific limits on catheter-to-vein ratios to reduce risks for cancer patients.
A new test with 'unprecedented early detection power' is being developed by a University of Houston researcher to detect cancer biomarkers in blood. The liquid biopsy method uses exosomes, small vesicles containing surface proteins and genetic materials, to improve the accuracy of measuring minimal residual disease (MRD) in cancer tumors.
Optical Genome Mapping (OGM) detects abnormalities in chromosomes extremely quickly and accurately, potentially replacing traditional techniques. This new technology has been proven effective in detecting hereditary disorders and could significantly improve patient care.
A microfilter device capable of detecting trace amounts of cancer cells in one mL of blood has been developed by a Kumamoto University research group. The device uses dynamic deformation and nucleic acid aptamers to separate and capture CTCs, achieving a high detection capability and selective detection rate.
Two studies by CU Cancer Center researchers found that chronic inflammation can serve as a key factor in the development of leukemia. Chronic inflammation reduces the fitness of normal cells, hindering their ability to reproduce and creating space for cancer-causing mutations to proliferate. The findings support the theory of adaptive ...
A blood test has been shown to be accurate enough for multi-cancer screening among people at higher risk of disease, detecting cancer signals from more than 50 types, and correctly identifying tumor locations. The test's sensitivity varies by type of cancer, with some cancers detected earlier than others.
A blood test detecting tiny amounts of circulating cancer DNA may identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery. The study found patients with a particular cancer DNA marker in their blood had a higher likelihood of cancer relapse, suggesting the potential for personalized treatment.
Researchers investigated the association between convalescent plasma treatment and mortality in hospitalized adults with hematologic cancers and COVID-19. The study found that convalescent plasma therapy was associated with improved survival rates among these patient groups.
A large retrospective study found that convalescent plasma from recovered COVID-19 patients can improve the likelihood of survival among blood cancer patients hospitalized with the virus. The therapy, which involves transfusing plasma rich in antibodies, was associated with a lower death rate compared to those who did not receive it.
Research shows that hospitalized individuals with active cancer are more likely to die from COVID-19 than those with a history of cancer or no cancer diagnosis. Patients with blood-related cancers face the greatest risk of death, while recent cancer therapy is not linked to worse outcomes.
A biomarker based on circulating tumour DNA (ctDNA) can predict the likelihood of bowel cancer recurrence after surgery and chemotherapy. The test measures ctDNA levels before and after treatment to provide real-time information on chemotherapy effectiveness.
Scientists found that platinum chemotherapy can cause genetic changes in children with neuroblastoma, leading to increased risk of secondary leukemia. The study's findings could lead to identifying high-risk children and tailoring their treatment plans to reduce this risk.
A new Penn Medicine study shows that blood cancer patients with lower antibody levels can rely on T cells to combat COVID-19. The research found that patients with higher CD8 T cell counts were more than three times likelier to survive than those with lower counts.
Researchers developed SaferSeqS to detect rare mutations in blood more efficiently and reduce sequencing errors. The technology has shown a marked improvement in sensitivity and specificity in detecting previously undetectable cancer-related mutations.
A new study has identified a genetic mutation in the CUX1 gene that contributes to the development of acute myeloid leukaemia. Targeting this pathway could lead to new targeted therapies for patients with poor-prognosis AML, which affects people of all ages and often requires intensive chemotherapy.
Researchers discovered a cancer-causing gene mutation that accelerates cerebral cavernous malformation growth, leading to seizures or stroke. Repurposing an anticancer drug showed promise in improving brain-vascular health and preventing bleeding into the brain tissue.
Researchers found that a specific gene called MPP8 suppresses the activity of 'jumping' genes, which can protect against certain blood cancers. This discovery may lead to new biomarkers and therapeutic targets for acute myeloid leukemia, the deadliest type of blood cancer.
A new study shows whole genome sequencing is at least as accurate and often better than conventional genetic tests for determining blood cancer treatment. The study found that sequencing identified additional genetic abnormalities in 17% of cases, changing the risk category for 19 patients.
Utah researchers identify mutation hotspots and find that approximately 2% of healthy participants had the same mutations as cancer patients. This study provides new insights into the development of blood cancers and may help identify people at risk.
A study by University of Birmingham scientists has shown that the balance of cells in blood is affected earlier than thought, particularly for families carrying mutant RUNX1 proteins. The research found that these mutations can change how genes respond and lead to different diseases.
Researchers at Indiana University School of Medicine have discovered a promising treatment approach for preventing acute graft-versus-host disease, a common complication of blood stem cell transplantation. The study found that using the oral drug sitagliptin reduces the risk of GVHD by inhibiting immune T cell activation.
A randomized clinical trial demonstrated the benefits of early integration of palliative care into oncology care for patients with high-risk AML. Patients who received integrated palliative and oncology care reported significantly better quality of life and lower levels of depression, anxiety, and PTSD.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
A recent study by Dana-Farber Cancer Institute scientists has found that clonal hematopoiesis can confer a health benefit in the setting of allogeneic stem cell or bone marrow transplants. Patients who received transplants from older donors with CH had a lower risk of relapse and longer survival compared to those without CH.